Home Blogs & InsightsNKG Immunodeficient Mouse Models: Ensuring Success in Immunotherapy Research

Autoimmunity & Inflammation

NKG Immunodeficient Mouse Models: Ensuring Success in Immunotherapy Research

Q: How has the development of immunodeficient mice evolved over the years?

Nude mice (1960s). The story began with the discovery of the athymic nude mouse in 1962. A Foxn1 mutation leaves these mice without a thymus and mature T cells, and in 1969 they hosted the first human tumor xenograft. But they keep functional B cells and highly active NK cells, which limits the human tissues they can accept. SCID mice (1983). A mutation in the Prkdc gene blocks both T and B cell development. However, many SCID mice become “leaky” as they age, producing some functional T and B cells, and their NK activity stays high. NOD-SCID mice (1990s). Moving the scid mutation onto the NOD background added the NOD strain’s innate immune defects, including reduced NK cell, macrophage and complement function, and greatly reduced leakiness. Residual NK activity and a short lifespan caused by thymic lymphomas remained limitations. Il2rg-null mice (2000s). The major breakthrough came from knocking out the IL-2 receptor common gamma chain gene (Il2rg) on the NOD-scid background, first in the NOG (2002) and NSG (2005) strains. This removed functional NK cells. Cyagen's NKG mouse (NOD.Cg-Prkdc^scid Il2rg^em1Cya/Cya) belongs to this generation: it lacks mature T cells, B cells and functional NK cells and is one of the most permissive hosts for human cell and tissue engraftment. Next-generation strains. Newer strains build on this platform. Some express human cytokines, some lack mouse MHC molecules, and some carry Kit mutations, so they better support human immune and hematopoietic cells.

Q: What were the key technical improvements in the latest generation of immunodeficient mice?

Loss of functional NK cells. Knocking out Il2rg (γc/CD132) blocks IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21 signaling, which prevents NK cell development. This is the main reason human cell engraftment is so efficient. Reduced innate rejection. The NOD background carries a SIRPα variant that binds human CD47 and lowers macrophage phagocytosis of human cells, along with a complement C5 deficiency. Stability. Leakiness is minimal, so mice rarely develop functional mouse T or B cells as they age. Longevity. Unlike NOD-SCID mice, Il2rg-null strains rarely develop thymic lymphomas and live much longer, which supports long-term studies such as humanized immune system models. Support for humanization. Derivative strains engineered to express human cytokines (e.g., IL-3, GM-CSF, SCF, IL-15) or to lack mouse MHC molecules better support specific human immune cell lineages and reduce GvHD.

Q: What support does Cyagen provide for the development of customized HIS models?

Cyagen offers a comprehensive platform ranging from our proprietary NKG host strains to fully validated HSC-Humanized and PBMC-Humanized models . Furthermore, we provide customized gene-editing services to create niche models that express specific human cytokines or MHC molecules, tailored to your specific drug target requirements.

Q: Are BALB/c mice considered immunodeficient models?

No. Standard BALB/c mice are immunocompetent, with a complete and functional immune system that includes T cells, B cells and natural killer (NK) cells. The confusion comes from the fact that several popular immunodeficient models are built on the BALB/c background: BALB/c (wild-type). An immunocompetent inbred strain widely used in immunology, antibody production, vaccine research and syngeneic tumor models. Its immune response naturally leans toward a Th2 type. BALB/c nude (Foxn1^nu). An immunodeficient variant. A Foxn1 mutation leaves these mice without a thymus, so they have very few mature T cells. They are also hairless, their most recognizable feature. C.B-17-scid. A BALB/c-congenic strain carrying the scid mutation, lacking both T and B cells.

Cyagen Technical Content Team | November 19, 2025

NKG Mice: The Premier Host for Human Cell Engraftment

Achieve high-fidelity results in CAR-T and PDX studies with Cyagen's NKG immunodeficient models.

Contents

01. In Vivo Precision: Why Immunodeficient Mouse Models Define R&D Success 02. Introducing NKG Mice: A Validated Platform for CAR-T and PDX Models 03. Accelerating Immunotherapy: A Proven Partnership in Preclinical Research 04. Advance Your Pipeline: Custom Immunodeficient Models for Discovery

Your CAR-T construct has just cleared its latest in vitro assay, showing potent and specific cytotoxicity. The data is clean, the mechanism is elegant, and the potential is immense. But between this promising result and a breakthrough publication lies the most unpredictable chasm in preclinical research: the in vivo study.

Have you ever felt that hesitation? The moment you select an animal model, you’re not just choosing a tool; you’re making a high-stakes bet. You’re betting that it will faithfully host your human-derived cells, that it won’t confound your results with residual immunity, and that it will survive long enough to yield meaningful data. A poor choice here doesn’t just mean a failed experiment. It means months of lost time, squandered funding, and a brilliant therapeutic concept stalled by the limitations of its platform. How many incredible discoveries have been derailed not by flawed science, but by a flawed vessel?

In Vivo Precision: Why Immunodeficient Mouse Models Define R&D Success

Now, imagine a different path. Imagine planning your next CAR-T, PDX (Patient-Derived Xenograft), or human hematopoietic stem cell (HSC) study with a sense of quiet confidence. Imagine the primary variable is your therapeutic agent, not the stability of your model.

In this reality, you move from in vitro success to in vivo validation in a seamless, accelerated workflow. Your engraftment rates are high and predictable, reducing inter-animal variability so that smaller cohorts can still deliver statistically powerful results. Your model is so profoundly immunodeficient that concerns over host rejection of your human cells simply fade into the background. You can focus on what truly matters: gathering the clean, translatable data that will illuminate your drug's true potential and pave the way for clinical translation. This isn’t a far-off ideal. It’s the strategic advantage researchers gain when they build their studies on a foundation of precisely engineered and rigorously validated immunodeficient models.

Introducing NKG Mice: A Validated Platform for CAR-T and PDX Models

Achieving this level of experimental clarity hinges on selecting a model that doesn’t just lack an immune system but is purpose-built for the specific demands of modern immunotherapy. While traditional nude and NOD scid mice laid the groundwork, today’s advanced therapies require a more sophisticated and reliable host.

For researchers pushing the boundaries of oncology and immunology, Cyagen’s portfolio of immunodeficient models provides the stable, validated foundation needed for success. The cornerstone of this portfolio, the NKG mouse, was engineered specifically to overcome the limitations of its predecessors.

Engineered for Unprecedented Receptivity: NKG mice were generated by deleting the Il2rg gene on the NOD-scid background. The scid mutation eliminates mature T and B cells, Il2rg deletion abolishes functional NK cells, and the NOD background contributes reduced complement activity and weak macrophage phagocytosis of human-derived cells.
Confidence in Engraftment: This superior design translates directly to world-class performance. In studies developing CAR-T therapies, our models have demonstrated a high successful engraftment rate, virtually eliminating the risk and cost of model failure.
A Versatile Platform for Advanced Research: The NKG’s extreme immunodeficiency makes it the ideal host for a wide range of applications, including:
- CAR-T Cell Therapy: Assess anti-tumor efficacy, expansion, and persistence with a model that won’t reject your engineered cells. Because infused human T cells can induce xenogeneic GvHD over time, study duration should be planned accordingly.
- Patient-Derived Xenografts (PDX): Engraft human tumor tissues with high success rates to create patient-relevant models for personalized medicine studies.
- Human Immune System Reconstitution: Study the complexities of human immunity by engrafting NKG mice with human CD34+ hematopoietic stem cells (HSCs) or peripheral blood mononuclear cells (PBMCs) to generate humanized immune system mice.
Built for Long-Term Studies: The robust health and extended lifespan of the NKG mouse support the long-term engraftment necessary to evaluate both the efficacy and the durability of novel treatments.

Accelerating Immunotherapy: A Proven Partnership in Preclinical Research

In science, trust isn't claimed; it's earned through data, repeatability, and shared success. For nearly two decades, Cyagen has worked alongside researchers in leading academic institutions and biotech firms, not as a vendor, but as a collaborative partner dedicated to solving the most difficult preclinical challenges.

The reliability of our immunodeficient models isn't just an internal metric; it's a conclusion validated by the global research community. The success of this partnership is documented in peer-reviewed publications, where scientists have leveraged our platforms to generate the pivotal data driving their fields forward. They chose these models because they needed a platform they could trust—one that had been rigorously characterized for immune cell deficiency, body weight, survival curves, and baseline physiology.

This extensive track record represents more than just a catalog of successful models. It’s a repository of shared experience. When labs developing next-generation immunotherapies partner with us, they aren't just acquiring an animal model; they are gaining access to a platform that has helped countless others like them turn visionary science into validated results. From establishing complex PDX models that retain key features of human tumor heterogeneity to confirming the in vivo potency of novel CAR-T constructs, our models have provided the biological canvas for discovery.

Advance Your Pipeline: Custom Immunodeficient Models for Discovery

Your research is too vital to be compromised by uncertainty. The time, resources, and intellectual energy you invest deserve a platform that de-risks your in vivo studies and amplifies your chances of success. It’s time to move your immunotherapy project forward on a foundation of proven reliability.

Take the next logical step on your research journey.

Explore our comprehensive portfolio of immunodeficient models to review detailed specifications, validation data, and application notes.

Or, for a more tailored approach, schedule a complimentary consultation with a scientific strategist to discuss your specific project goals and identify the optimal model to accelerate your path to discovery.